Though the role of genes in heart disease is appreciated, there is currently little understanding of the mechanism by which the transcription factor NF-kB contributes to the antithetical processes of cardioprotection and ischemia/reperfusion (I/R) injury. This Critical Gap In Knowledge prevents the successful development of therapies employing NF-kB inhibition or cytokine blockade in cardiovascular disease. The objective of the proposal is to fill this knowledge gap;to develop a comprehensive understanding of the mechanism by which NF-kB and NF-kB-dependent gene expression networks affect I/R injury, cardioprotection, post-I/R dysfunction and heart failure. We offer the central hypothesis that NF-kB mediates differential responses to different stimuli by regulating distinct sets of NF-kB-dependent genes. We propose three specific aims;1) Delineate the sets of NF-kB-dependent genes that underlie the antithetical effects of NF-kB upon cell death after I/R and PO, 2) Determine the transcriptional mechanism by which NF-kB modulates gene expression to evoke cell death after I/R and cell survival after PO, 3) Determine the biological effects and therapeutic potential of PGAA polyplexes during acute and chronic post-ischemic disease in vivo. The approach is to employ an hypothesis-driven microarray strategy that takes advantage of our IkBDN mice (block NF-kB) to delineate NF-kB-dependent genes functionally associated with NF-kB-dependent pro-injury and cardioprotective effects. We will also employ an innovative non-viral polymeric nucleic acid delivery technology (PGAA) to block NF-kB activation (decoys) and to silence NF-kB-dependent genes (siRNA) in vivo. We expect that the results will provide a mechanistic understanding of how NF-kB-dependent genes underlie differential responses in the heart. Public Health Relevance: The proposed research is significant because it will lead to identification of new therapeutic targets and development of novel therapies for ischemic heart disease. The proposal develops a novel and innovative set of reagents for basic science that can be used for DNA and siRNA delivery in vivo. The proposal is highly translational in that it develops the therapeutic use of PGAA-mediated decoy and siRNA delivery in pre- clinical studies.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL091478-04
Application #
8077319
Study Section
Myocardial Ischemia and Metabolism Study Section (MIM)
Program Officer
Schwartz, Lisa
Project Start
2008-07-15
Project End
2013-05-31
Budget Start
2011-06-01
Budget End
2013-05-31
Support Year
4
Fiscal Year
2011
Total Cost
$601,621
Indirect Cost
Name
University of Cincinnati
Department
Pharmacology
Type
Schools of Medicine
DUNS #
041064767
City
Cincinnati
State
OH
Country
United States
Zip Code
45221
Yu, Bin; Yang, Yueting; Liu, Huan et al. (2016) Clusterin/Akt Up-Regulation Is Critical for GATA-4 Mediated Cytoprotection of Mesenchymal Stem Cells against Ischemia Injury. PLoS One 11:e0151542
Haar, Lauren; Ren, Xiaoping; Liu, Yong et al. (2014) Acute consumption of a high-fat diet prior to ischemia-reperfusion results in cardioprotection through NF-?B-dependent regulation of autophagic pathways. Am J Physiol Heart Circ Physiol 307:H1705-13
Thomas, Candice M; Yong, Qian Chen; Rosa, Rodolfo M et al. (2014) Cardiac-specific suppression of NF-?B signaling prevents diabetic cardiomyopathy via inhibition of the renin-angiotensin system. Am J Physiol Heart Circ Physiol 307:H1036-45
Rubinstein, Jack; Lasko, Valerie M; Koch, Sheryl E et al. (2014) Novel role of transient receptor potential vanilloid 2 in the regulation of cardiac performance. Am J Physiol Heart Circ Physiol 306:H574-84
Lam, Chi Keung; Zhao, Wen; Cai, Wenfeng et al. (2013) Novel role of HAX-1 in ischemic injury protection involvement of heat shock protein 90. Circ Res 112:79-89
Koch, Sheryl E; Haworth, Kevin J; Robbins, Nathan et al. (2013) Age- and gender-related changes in ventricular performance in wild-type FVB/N mice as evaluated by conventional and vector velocity echocardiography imaging: a retrospective study. Ultrasound Med Biol 39:2034-43
Koch, Sheryl E; Tranter, Michael; Robbins, Nathan et al. (2013) Probenecid as a noninjurious positive inotrope in an ischemic heart disease murine model. J Cardiovasc Pharmacol Ther 18:280-9
Zuo, Shi; Jones, W Keith; Li, Hongxia et al. (2012) Paracrine effect of Wnt11-overexpressing mesenchymal stem cells on ischemic injury. Stem Cells Dev 21:598-608
Koch, Sheryl E; Gao, Xiaoqian; Haar, Lauren et al. (2012) Probenecid: novel use as a non-injurious positive inotrope acting via cardiac TRPV2 stimulation. J Mol Cell Cardiol 53:134-44
Tranter, Michael; Liu, Yemin; He, Suiwen et al. (2012) In vivo delivery of nucleic acids via glycopolymer vehicles affords therapeutic infarct size reduction in vivo. Mol Ther 20:601-8

Showing the most recent 10 out of 18 publications